XBiotech's Phase III results show Xilonix's 76% advanced colorectal cancer improvement vs placebo

2 July 2016

USA-based XBiotech (Nasdaq: XBIT) has achieved highly promising Phase III results in advanced colorectal cancer (CRC) with its lead monoclonal antibody immunotherapy, Xilonix.

The data shows a 76% relative improvement against placebo in a composite measure of multiple symptoms – pain, fatigue and appetite and muscle loss – that predict disease progression and poor prognosis for survival.

These results, presented at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC), also showed a notable lack of toxicity associated with Xilonix treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK